Clinical trials have demonstrated the safety and immunogenicity of a dual-purpose vaccine designed to mitigate the impact of Lassa fever and rabies in high-burden regions.

臨床試驗已證明一種雙用途疫苗的安全性與免疫原性，該疫苗旨在減輕高負擔地區拉沙熱與狂犬病的影響。

The epidemiological landscape of Western and Sub-Saharan Africa is characterized by a significant prevalence of both rabies and Lassa fever. The latter, a rodent-borne viral hemorrhagic disease, is estimated by the Africa Centers for Disease Control and Prevention to cause 300,000 infections and 5,000 fatalities annually, though these figures are posited to be underestimates due to surveillance deficits. Particular morbidity is noted in late-term pregnancies, where mortality rates exceed 80%. Concurrently, rabies remains a critical threat, characterized by near-universal fatality upon the onset of clinical symptoms.

西非與撒哈拉以南非洲的流行病學情況以狂犬病與拉沙熱的高盛行率為特徵。後者是一種由齧齒動物傳播的病毒性出血熱，根據非洲疾病控制與預防中心的估計，每年造成 30 萬例感染與 5,000 例死亡，但由於監測不足，這些數據被認為是被低估了。在孕晚期的發病率尤其顯著，死亡率超過 80%。同時，狂犬病仍是一個關鍵威脅，其特點是臨床症狀出現後幾乎必然導致死亡。

To address these concurrent threats, researchers from the University of Maryland School of Medicine's Center for Vaccine Development and Global Health developed a bivalent vaccine. A study published in Nature Medicine involved 54 healthy adult participants in the United States, who were administered two doses of the candidate vaccine at 28-day intervals. The results indicated that the vaccine was safe, with no serious adverse reactions reported, and successfully induced immune responses against both target viruses, whereas the control group exhibited responses only to rabies. The trial is currently ongoing, with a total observation period of 394 days post-vaccination.

為了應對這些同時存在的威脅，馬里蘭大學醫學院疫苗開發與全球健康中心的研究人員開發了一種二價疫苗。一篇發表在《自然醫學》的研究涉及 54 名美國健康成年參與者，他們每隔 28 天接種一次候選疫苗，共兩劑。結果顯示該疫苗具有安全性，未報告嚴重不良反應，並成功誘導出針對兩種目標病毒的免疫反應，而對照組僅對狂犬病產生反應。該試驗目前仍在進行中，接種後的總觀察期為 394 天。

From a logistical perspective, the vaccine's capacity for lyophilization facilitates distribution in environments lacking robust cold-chain infrastructure. Furthermore, institutional projections suggest that climatic shifts may expand the ecological suitability for Lassa virus transmission. Dean Mark Gladwin has asserted that such environmental changes could increase the global population at risk to approximately 700 million, with a substantial increase in affected African nations by 2070.

從物流角度來看，該疫苗的冷凍乾燥能力有助於在缺乏強大冷鏈基礎設施的環境中進行分發。此外，機構預測顯示，氣候變遷可能會擴大拉沙病毒傳播的生態適用範圍。院長 Mark Gladwin 主張，此類環境變化可能會將全球風險人口增加至約 7 億，到 2070 年，受影響的非洲國家將大幅增加。

The dual vaccine has demonstrated initial safety and efficacy, with further clinical trials contingent upon the maintenance of elevated immune responses.

該雙疫苗已證明初步的安全性與有效性，進一步的臨床試驗將取決於免疫反應能否維持在高水平。